CDC Panel (Barely) Prefers Shingrix Shingles Vaccine Over Zostavax
In 8-7 vote, Advisory Committee on Immunization Practices recommends GSK's Shingrix as preferred shingles vaccine given its higher efficacy compared to Merck's Zostavax.
You may also be interested in...
The shingles vaccine could potentially be used in about three million immunocompromised people, according to GSK, but CDC’s advisory committee will weigh in with recommendations.
Phase III trials found vaccine effectiveness was 68.2% in recipients with autologous hematopoietic stem cell transplant and 87.2% in those with hematologic malignancies, GSK tells Advisory Committee on Immunization Practices.
With few near-term catalysts, GSK's R&D strategy may leave some investors underwhelmed, but President-R&D Hal Barron is focused on making deep cultural and scientific changes at the big pharma. He laid out his initial turnaround plan July 25.